<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898234</url>
  </required_header>
  <id_info>
    <org_study_id>012012</org_study_id>
    <nct_id>NCT01898234</nct_id>
  </id_info>
  <brief_title>Dialysis Membranes and Hemodynamic Tolerance</brief_title>
  <official_title>Assessment of Subjective and Hemodynamic Tolerance of Different High- and Low-flux Dialysis Membranes in Patients Undergoing Chronic Intermittent Hemodialysis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Regionale di Locarno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Regionale di Locarno</source>
  <brief_summary>
    <textblock>
      Background:

      High- and low-flux dialysis membranes made of different materials may correlate with various
      hemodynamic tolerance profiles. This study aims to investigate hemodynamic response and
      incidence of hypotensive episodes by comparing some of the most commonly used high- and
      low-flux dialyzers.

      Methodology:

      The study was designed as an open label, randomized, cross-over investigation, including 25
      patients undergoing chronic hemodialysis. Four polysulfone dialyzers of 1.8 m2, A (Revaclear,
      Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux,
      Fresenius), were compared with each other. The hemodynamic profile was assessed with a
      non-invasive technique and patients were asked to provide tolerance feedback through a
      questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparative evaluation of mean hemodynamic parameters (i.e. systolic and diastolic blood pressure, peripheral resistance and cardiac output) during dialysis</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>comparative evaluation of subjective tolerance across the various membranes</measure>
    <time_frame>4 weeks</time_frame>
    <description>As to the assessment of subjective tolerance, we decided to administer the questionnaire designed by Cruz et al. [Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am. J. Kidney Dis. 1999 Mag;33(5):920-926] then modified by Teruel et al. [Teruel JL, Martins J, Merino JL, Fernández Lucas M, Rivera M, Marcén R, et al. Temperature of the dialysis bath and hemodialysis tolerance. Nefrología: PublicaciónOficial De La Sociedad Española Nefrologia. 2006;26(4):461-468] and to integrate it with a 1 to 10 numerical scale to assess patient well-being</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparative evaluation of Kt/V and of beta-2 microglobulin removal</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparative analysis of the incidence of symptomatic and non-symptomatic systolic pressure drops (&gt; 20 mmHg)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Dialysis Membranes and Hemodynamic Tolerance</condition>
  <arm_group>
    <arm_group_label>Revaclear</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Helixone high flux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xevonta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Helixone low flux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revaclear</intervention_name>
    <description>Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other</description>
    <arm_group_label>Revaclear</arm_group_label>
    <other_name>-Revaclear, Gambro 1.8 m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helixone high flux</intervention_name>
    <description>Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other</description>
    <arm_group_label>Helixone high flux</arm_group_label>
    <other_name>Helixone high flux, Fresenius 1.8 m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xevonta</intervention_name>
    <description>Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other</description>
    <arm_group_label>Xevonta</arm_group_label>
    <other_name>Xevonta, BBraun 1.8 m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helixone low flux</intervention_name>
    <description>Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other</description>
    <arm_group_label>Helixone low flux</arm_group_label>
    <other_name>Helixone low flux, Fresenius 1.8 m2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 and older

          -  ability to understand the information presented and sign the informed consent

          -  chronic hemodialysis for at least 8 weeks

          -  stable dialysis prescriptions and modality in the 2 weeks prior to protocol
             implementation

        Exclusion Criteria:

          -  mental illness;

          -  inability to understand the information presented and sign the informed consent;

          -  acute disease requiring hospitalization at the time of patient enrolment

          -  pregnancy and breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Gabutti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Regionale Locarno</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Regionale di Locarno</name>
      <address>
        <city>Locarno</city>
        <state>Ticino</state>
        <zip>6928</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Regionale di Locarno</investigator_affiliation>
    <investigator_full_name>Luca Gabutti, MD</investigator_full_name>
    <investigator_title>Prof, Head of Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Hemodynamics</keyword>
  <keyword>intradialytic hypotension</keyword>
  <keyword>subjective tolerance</keyword>
  <keyword>dialysis membranes</keyword>
  <keyword>high flux</keyword>
  <keyword>low flux</keyword>
  <keyword>hemodialysis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

